Related Experiment Videos
Transforming growth factor-beta and ischemic brain injury
Alain Buisson1, Sylvain Lesne, Fabian Docagne
1Université de CAEN, UMR CNRS 6551, IFR 47, Feder, Centre CYCERON, bd H. Becquerel, Caen, France.
Cellular and Molecular Neurobiology
|September 30, 2003
Summary
Transforming Growth Factor-beta1 (TGF-beta1) shows neuroprotective effects against stroke-related neuronal death. Targeting TGF-beta1 signaling may offer new therapeutic strategies for stroke treatment.
Area of Science:
- Neuroscience
- Molecular Biology
- Pathology
Background:
- Neuronal death via necrosis and apoptosis are key features of stroke.
- Tissue plasminogen activator (t-PA) is the sole approved stroke treatment.
- Transforming Growth Factor-beta1 (TGF-beta1) is upregulated in the brain after ischemic damage.
Purpose of the Study:
- To investigate the neuroprotective role of TGF-beta1 in stroke.
- To elucidate the mechanisms underlying TGF-beta1's protective effects.
Main Methods:
- In vitro studies examining TGF-beta1's effects on excitotoxicity.
- Analysis of TGF-beta1's impact on NMDA-induced neuronal death.
- Investigating TGF-beta1's role in staurosporine-induced neuronal death models.
Main Results:
- TGF-beta1 demonstrated neuroprotection against ischemia-induced neuronal death.
- TGF-beta1 inhibited t-PA-potentiated NMDA-induced neuronal death by upregulating plasminogen activator inhibitor-1 (PAI-1) in astrocytes.
- TGF-beta1 acted as an antiapoptotic factor via extracellular signal-regulated kinase 1/2 (Erk1/2) activation and Bad protein phosphorylation.
Conclusions:
- TGF-beta1 exhibits significant neuroprotective and antiapoptotic properties in stroke models.
- TGF-beta1 signaling pathways and modulated genes are potential therapeutic targets for stroke.
- Further research into TGF-beta1 could lead to novel stroke treatments.